Search

Your search keyword '"Forster, Martin"' showing total 964 results
Start Over Author "Forster, Martin"
964 results on '"Forster, Martin"'

1. CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Author

Mehanna, Hisham, Gaunt, Piers, Kong, Anthony, Hartley, Andrew, Sanghera, Paul, Forster, Martin, Sen, Mehmet, Paleri, Vinidh, Fong, Charles, Geropantas, Dinos, Srinivasan, Devraj, Garikipati, Satya, Moleron, Rafael, Casswell, Georgina, Aynsley, Eleanor, Ward, Amy, O’Toole, Lorcan, Mirza, Arafat, Firth, Charlotte, Humphreys, Isla, Fulton-Lieuw, Tessa, Roques, Tom, and Nankivell, Paul

Published
2024
Full Text
View/download PDF

2. Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial

Author

Lee, Siow Ming, Hewish, Madeleine, Ahmed, Samreen, Papadatos-Pastos, Dionysis, Karapanagiotou, Eleni, Blackhall, Fiona, Ford, Amy, Young, Robin, Garcia, Angel, Arora, Arvind, Hollingdale, Abigail, Ahmad, Tanya, Forster, Martin, Greystoke, Alastair, Bremner, Fion, Rudd, Robin, Farrelly, Laura, Vaja, Simran, and Hackshaw, Allan

Published
2025
Full Text
View/download PDF

4. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

Author

Krebs, Matthew G., Forster, Martin, Majem, Margarita, Peguero, Julio, Iams, Wade, Clay, Tim, Roxburgh, Patricia, Doger, Bernard, Bajaj, Pawan, Barba, Andres, Perera, Suvini, Mueller, Christian, and Triebel, Frédéric

Published
2024
Full Text
View/download PDF

5. Psychometric Properties of the Parental Stress Scale in Swedish Parents of Children with and without Neurodevelopmental Conditions

Author

Lindström Therese, Bergman Tiina Holmberg, Annerstedt Mathilde, Forster Martin, Bölte Sven, and Hirvikoski Tatja

Subjects
parental stress, assessment, caregiver burden, neurodevelopmental condition, parental adhd, Psychiatry, RC435-571, Psychology, BF1-990
Abstract

Parents of children with neurodevelopmental conditions (NDC) are at risk of experiencing elevated levels of parental stress. Access to robust instruments to assess parental stress is important in both clinical and research contexts. Objective: We aimed to evaluate the psychometric properties of a Swedish version of the Parental Stress Scale (PSS), completed by parents of 3- to 17-year-old children, with and without NDCs.

Published
2024
Full Text
View/download PDF

7. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

Author

Waterhouse, David M., Rothschild, Sacha, Dooms, Christophe, Mennecier, Bertrand, Bozorgmehr, Farastuk, Majem, Margarita, van den Heuvel, Michel H., Linardou, Helena, Chul Cho, Byoung, Roberts-Thomson, Rachel, Tanaka, Kentaro, Blais, Normand, Schvartsman, Gustavo, Holmskov Hansen, Karin, Chmielewska, Izabela, Forster, Martin D., Giannopoulou, Christina, Stollenwerk, Björn, Obiozor, Cynthia C., Wang, Yang, and Novello, Silvia

Published
2024
Full Text
View/download PDF

8. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

Author

Frankell, Alexander M., Dietzen, Michelle, Al Bakir, Maise, Lim, Emilia L., Karasaki, Takahiro, Ward, Sophia, Veeriah, Selvaraju, Colliver, Emma, Huebner, Ariana, Bunkum, Abigail, Hill, Mark S., Grigoriadis, Kristiana, Moore, David A., Black, James R. M., Liu, Wing Kin, Thol, Kerstin, Pich, Oriol, Watkins, Thomas B. K., Naceur-Lombardelli, Cristina, Cook, Daniel E., Salgado, Roberto, Wilson, Gareth A., Bailey, Chris, Angelova, Mihaela, Bentham, Robert, Martínez-Ruiz, Carlos, Abbosh, Christopher, Nicholson, Andrew G., Le Quesne, John, Biswas, Dhruva, Rosenthal, Rachel, Puttick, Clare, Hessey, Sonya, Lee, Claudia, Prymas, Paulina, Toncheva, Antonia, Smith, Jon, Xing, Wei, Nicod, Jerome, Price, Gillian, Kerr, Keith M., Naidu, Babu, Middleton, Gary, Blyth, Kevin G., Fennell, Dean A., Forster, Martin D., Lee, Siow Ming, Falzon, Mary, Hewish, Madeleine, Shackcloth, Michael J., Lim, Eric, Benafif, Sarah, Russell, Peter, Boleti, Ekaterini, Krebs, Matthew G., Lester, Jason F., Papadatos-Pastos, Dionysis, Ahmad, Tanya, Thakrar, Ricky M., Lawrence, David, Navani, Neal, Janes, Sam M., Dive, Caroline, Blackhall, Fiona H., Summers, Yvonne, Cave, Judith, Marafioti, Teresa, Herrero, Javier, Quezada, Sergio A., Peggs, Karl S., Schwarz, Roland F., Van Loo, Peter, Miedema, Daniël M., Birkbak, Nicolai J., Hiley, Crispin T., Hackshaw, Allan, Zaccaria, Simone, Jamal-Hanjani, Mariam, McGranahan, Nicholas, and Swanton, Charles

Published
2024
Full Text
View/download PDF

12. The evolution of non-small cell lung cancer metastases in TRACERx

Author

Al Bakir, Maise, Huebner, Ariana, Martínez-Ruiz, Carlos, Grigoriadis, Kristiana, Watkins, Thomas B. K., Pich, Oriol, Moore, David A., Veeriah, Selvaraju, Ward, Sophia, Laycock, Joanne, Johnson, Diana, Rowan, Andrew, Razaq, Maryam, Akther, Mita, Naceur-Lombardelli, Cristina, Prymas, Paulina, Toncheva, Antonia, Hessey, Sonya, Dietzen, Michelle, Colliver, Emma, Frankell, Alexander M., Bunkum, Abigail, Lim, Emilia L., Karasaki, Takahiro, Abbosh, Christopher, Hiley, Crispin T., Hill, Mark S., Cook, Daniel E., Wilson, Gareth A., Salgado, Roberto, Nye, Emma, Stone, Richard Kevin, Fennell, Dean A., Price, Gillian, Kerr, Keith M., Naidu, Babu, Middleton, Gary, Summers, Yvonne, Lindsay, Colin R., Blackhall, Fiona H., Cave, Judith, Blyth, Kevin G., Nair, Arjun, Ahmed, Asia, Taylor, Magali N., Procter, Alexander James, Falzon, Mary, Lawrence, David, Navani, Neal, Thakrar, Ricky M., Janes, Sam M., Papadatos-Pastos, Dionysis, Forster, Martin D., Lee, Siow Ming, Ahmad, Tanya, Quezada, Sergio A., Peggs, Karl S., Van Loo, Peter, Dive, Caroline, Hackshaw, Allan, Birkbak, Nicolai J., Zaccaria, Simone, Jamal-Hanjani, Mariam, McGranahan, Nicholas, and Swanton, Charles

Published
2023
Full Text
View/download PDF

13. The evolution of lung cancer and impact of subclonal selection in TRACERx

Author

Frankell, Alexander M., Dietzen, Michelle, Al Bakir, Maise, Lim, Emilia L., Karasaki, Takahiro, Ward, Sophia, Veeriah, Selvaraju, Colliver, Emma, Huebner, Ariana, Bunkum, Abigail, Hill, Mark S., Grigoriadis, Kristiana, Moore, David A., Black, James R. M., Liu, Wing Kin, Thol, Kerstin, Pich, Oriol, Watkins, Thomas B. K., Naceur-Lombardelli, Cristina, Cook, Daniel E., Salgado, Roberto, Wilson, Gareth A., Bailey, Chris, Angelova, Mihaela, Bentham, Robert, Martínez-Ruiz, Carlos, Abbosh, Christopher, Nicholson, Andrew G., Le Quesne, John, Biswas, Dhruva, Rosenthal, Rachel, Puttick, Clare, Hessey, Sonya, Lee, Claudia, Prymas, Paulina, Toncheva, Antonia, Smith, Jon, Xing, Wei, Nicod, Jerome, Price, Gillian, Kerr, Keith M., Naidu, Babu, Middleton, Gary, Blyth, Kevin G., Fennell, Dean A., Forster, Martin D., Lee, Siow Ming, Falzon, Mary, Hewish, Madeleine, Shackcloth, Michael J., Lim, Eric, Benafif, Sarah, Russell, Peter, Boleti, Ekaterini, Krebs, Matthew G., Lester, Jason F., Papadatos-Pastos, Dionysis, Ahmad, Tanya, Thakrar, Ricky M., Lawrence, David, Navani, Neal, Janes, Sam M., Dive, Caroline, Blackhall, Fiona H., Summers, Yvonne, Cave, Judith, Marafioti, Teresa, Herrero, Javier, Quezada, Sergio A., Peggs, Karl S., Schwarz, Roland F., Van Loo, Peter, Miedema, Daniël M., Birkbak, Nicolai J., Hiley, Crispin T., Hackshaw, Allan, Zaccaria, Simone, Jamal-Hanjani, Mariam, McGranahan, Nicholas, and Swanton, Charles

Published
2023
Full Text
View/download PDF

17. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

18. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Author

Zauderer, Marjorie G, Szlosarek, Peter W, Le Moulec, Sylvestre, Popat, Sanjay, Taylor, Paul, Planchard, David, Scherpereel, Arnaud, Koczywas, Marianna, Forster, Martin, Cameron, Robert B, Peikert, Tobias, Argon, Evren Kocabaş, Michaud, Neil R, Szanto, Attila, Yang, Jay, Chen, Yingxue, Kansra, Vikram, Agarwal, Shefali, and Fennell, Dean A

Published
2022
Full Text
View/download PDF

19. Use of heart failure medical therapy before and after a cancer diagnosis: A longitudinal study.

Author

Ju, Chengsheng, Lau, Wallis C.Y., Manisty, Charlotte, Chambers, Pinkie, Brauer, Ruth, Forster, Martin D., Mackenzie, Isla S., and Wei, Li

Subjects
MINERALOCORTICOID receptors, PATIENT compliance, CANCER diagnosis, HEART failure, MEDICAL research
Abstract

Aims: We aim to evaluate change in the use of prognostic guideline‐directed medical therapies (GDMTs) for heart failure (HF) before and after a cancer diagnosis as well as the matched non‐cancer controls, including renin‐angiotensin‐system inhibitors (RASIs), beta‐blockers, and mineralocorticoid receptor antagonists (MRAs). Methods and results: We conducted a longitudinal study in patients with HF in the UK Clinical Practice Research Datalink between 2005 and 2021. We selected patients with probable HF with reduced ejection fraction (HFrEF) based on diagnostic and prescription records. We described the longitudinal trends in the use and dosing of GDMTs before and after receiving an incident cancer diagnosis. HF patients with cancer were matched with a 1:1 ratio to HF patients without cancer to investigate the association between cancer diagnosis and treatment adherence, persistence, initiation, and dose titration as odds ratios (ORs) with 95% confidence intervals (CIs) using multivariable logistic regression models. Of 8504 eligible HFrEF patients with incident cancer, 4890 were matched to controls without cancer. The mean age was 75.7 (±8.4) years and 73.9% were male. In the 12 months following a cancer diagnosis, patients experienced reductions in the use and dosing of GDMT. Compared with the non‐cancer controls, patients with cancer had higher risks for poor adherence for all three medication classes (RASIs: OR = 1.51, 95% CI = 1.35–1.68; beta‐blockers: OR = 1.22, 95% CI = 1.08–1.37; MRAs: OR = 1.31, 95% CI = 1.08–1.59) and poor persistence (RASIs: OR = 2.04, 95% CI = 1.75–2.37; beta‐blockers: OR = 1.35, 95% CI = 1.12–1.63; MRAs: OR = 1.49, 95% CI = 1.16–1.93), and higher risks for dose down‐titration for RASIs (OR = 1.69, 95% CI = 1.40–2.04) and beta‐blockers (OR = 1.31, 95% CI = 1.05–1.62). Cancer diagnosis was not associated with treatment initiation or dose up‐titration. Event rates for HF hospitalization and mortality were higher in patients with poor adherence or persistence to GDMTs. Conclusions: Following a cancer diagnosis, patients with HFrEF were more likely to have reduced use of GDMTs for HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.

Author

Steventon, Luke, Man, Kenneth K C, Nicum, Shibani, Miller, Rowan E, Peleg Hasson, Shira, Shah, Samixa, Baser, Michael, Kipps, Emma, Forster, Martin D, Almossawi, Ofran, and Chambers, Pinkie

Subjects
MORTALITY, RESEARCH funding, OVARIAN tumors, RETROSPECTIVE studies, CANCER patients, DECISION making in clinical medicine, DESCRIPTIVE statistics, LONGITUDINAL method, ADJUVANT chemotherapy, KAPLAN-Meier estimator, QUALITY of life, MEDICAL records, ACQUISITION of data, COMBINED modality therapy, TREATMENT delay (Medicine), TUMOR classification, CONFIDENCE intervals, OVERALL survival, PROPORTIONAL hazards models, REGRESSION analysis
Abstract

Introduction Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management. Methods This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015. The frequency of inter-cycle delays >7 days was calculated using drug administration dates. Kaplan-Meier estimates were used to compare 2-year overall survival (OS) between patients who were delayed and those treated to schedule. Cox proportional hazards regression was used to investigate the impact of treatment delay on all-cause mortality. Inverse probability of treatment weighting propensity scores were used to adjust for confounding variables. Results Delays >7 days occurred in 35.3% of patients. Two-year OS probability was 62.7% in patients who experienced treatment delays >7 days (95% CI, 58.7-66.9) compared to 69.1% in those treated to schedule (95% CI, 66.2-72.0). Delays were not significantly associated with all-cause mortality when adjusted for confounders (HR 1.00 95% CI, 0.83-1.20, P  = .9). Conclusions Delays to chemotherapy treatment were not significantly associated with worsened survival in patients with advanced-stage ovarian cancer. These results can inform clinical decision making that prioritize toxicity management and quality of life for those treated with chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. DNA methylation-based classification of sinonasal tumors

Author

Jurmeister, Philipp, Glöß, Stefanie, Roller, Renée, Leitheiser, Maximilian, Schmid, Simone, Mochmann, Liliana H., Payá Capilla, Emma, Fritz, Rebecca, Dittmayer, Carsten, Friedrich, Corinna, Thieme, Anne, Keyl, Philipp, Jarosch, Armin, Schallenberg, Simon, Bläker, Hendrik, Hoffmann, Inga, Vollbrecht, Claudia, Lehmann, Annika, Hummel, Michael, Heim, Daniel, Haji, Mohamed, Harter, Patrick, Englert, Benjamin, Frank, Stephan, Hench, Jürgen, Paulus, Werner, Hasselblatt, Martin, Hartmann, Wolfgang, Dohmen, Hildegard, Keber, Ursula, Jank, Paul, Denkert, Carsten, Stadelmann, Christine, Bremmer, Felix, Richter, Annika, Wefers, Annika, Ribbat-Idel, Julika, Perner, Sven, Idel, Christian, Chiariotti, Lorenzo, Della Monica, Rosa, Marinelli, Alfredo, Schüller, Ulrich, Bockmayr, Michael, Liu, Jacklyn, Lund, Valerie J., Forster, Martin, Lechner, Matt, Lorenzo-Guerra, Sara L., Hermsen, Mario, Johann, Pascal D., Agaimy, Abbas, Seegerer, Philipp, Koch, Arend, Heppner, Frank, Pfister, Stefan M., Jones, David T. W., Sill, Martin, von Deimling, Andreas, Snuderl, Matija, Müller, Klaus-Robert, Forgó, Erna, Howitt, Brooke E., Mertins, Philipp, Klauschen, Frederick, and Capper, David

Published
2022
Full Text
View/download PDF

24. FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).

Author

Le, Xiuning, primary, Spira, Alexander I., additional, Gadgeel, Shirish M., additional, Riess, Jonathan W., additional, Yu, Yan, additional, Zhao, Yanqiu, additional, Cheng, Ying, additional, Juan-Vidal, Oscar, additional, Gao, Bo, additional, Yoh, Kiyotaka, additional, Forster, Martin, additional, Kitazono, Satoru, additional, Hayashi, Hidetoshi, additional, Planchard, David, additional, Jiang, Yong, additional, Baio, Nichole, additional, Kowanetz, Marcin, additional, Leung, William, additional, Hsu, Jerry Y., additional, and Wang, Jie, additional

Published
2024
Full Text
View/download PDF

25. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Author

Abbosh, Chris, Shiu, Kai-Keen, Bridgewater, John, Hochhauser, Daniel, Forster, Martin, Lee, Siow-Ming, Ahmad, Tanya, Papadatos-Pastos, Dionysis, Janes, Sam, Van Loo, Peter, Enfield, Katey, McGranahan, Nicholas, Huebner, Ariana, Beck, Stephan, Parker, Peter, Walczak, Henning, Enver, Tariq, Hynds, Rob, Sinclair, Ron, Lok, Chi-wah, Rhodes, Zoe, Moore, David, Khiroya, Reena, Trevisan, Giorgia, Ellery, Peter, Linch, Mark, Brandner, Sebastian, Hiley, Crispin, Veeriah, Selvaraju, Razaq, Maryam, Shaw, Heather, Attard, Gert, Akther, Mita Afroza, Naceur-Lombardelli, Cristina, Manzano, Lizi, Al-Bakir, Maise, Summan, Simranpreet, Kanu, Nnenna, Ward, Sophie, Asghar, Uzma, Lim, Emilia, Gishen, Faye, Tookman, Adrian, Stone, Paddy, Stirling, Caroline, Hunter, Nikki, Vaughan, Sarah, Mangwende, Mary, Spain, Lavinia, Yan, Haixi, Shum, Ben, Carlyle, Eleanor, Yousaf, Nadia, Popat, Sanjay, Curtis, Olivia, Stamp, Gordon, Toncheva, Antonia, Nye, Emma, Murra, Aida, Korteweg, Justine, Josephs, Debra, Chandra, Ashish, Spicer, James, Stewart, Ruby, Iredale, Lara-Rose, Mackay, Tina, Deakin, Ben, Enting, Debra, Rudman, Sarah, Ghosh, Sharmistha, Karapagniotou, Lena, Pintus, Elias, Tutt, Andrew, Howlett, Sarah, Michalarea, Vasiliki, Brenton, James, Caldas, Carlos, Fitzgerald, Rebecca, Jimenez-Linan, Merche, Provenzano, Elena, Cluroe, Alison, Stewart, Grant, Watts, Colin, Gilbertson, Richard, McDermott, Ultan, Tavare, Simon, Beddowes, Emma, Roxburgh, Patricia, Biankin, Andrew, Chalmers, Anthony, Fraser, Sioban, Oien, Karin, Kidd, Andrew, Blyth, Kevin, Krebs, Matt, Blackhall, Fiona, Summers, Yvonne, Dive, Caroline, Marais, Richard, Gomes, Fabio, Carter, Mat, Dransfield, Jo, Le Quesne, John, Fennell, Dean, Shaw, Jacqui, Naidu, Babu, Baijal, Shobhit, Tanchel, Bruce, Langman, Gerald, Robinson, Andrew, Collard, Martin, Cockcroft, Peter, Ferris, Charlotte, Bancroft, Hollie, Kerr, Amy, Middleton, Gary, Webb, Joanne, Kadiri, Salma, Colloby, Peter, Olisemeke, Bernard, Wilson, Rodelaine, Tomlinson, Ian, Jogai, Sanjay, Ottensmeier, Christian, Harrison, David, Loda, Massimo, Flanagan, Adrienne, McKenzie, Mairead, Hackshaw, Allan, Ledermann, Jonathan, Chan, Kitty, Sharp, Abby, Farrelly, Laura, Bridger, Hayley, Challacombe, Ben, Chowdhury, Simon, Drake, William, Fernando, Archana, Harrison-Phipps, Karen, Hazell, Steve, Hill, Peter, Horsfield, Catherine, O'Brien, Tim, Olsburgh, Jonathon, Polson, Alexander, Varia, Mary, Verma, Hema, Au, Lewis, Hatipoglu, Emine, Robert de Massy, Marc, Litchfield, Kevin, Beattie, Gordon, Rowan, Andrew, Schnidrig, Desiree, Thompson, Rachael, Byrne, Fiona, Horswell, Stuart, Fotiadis, Nicos, Nicol, David, Shepherd, Scott T.C., Fendler, Annika, Mason, Robert, Del Rosario, Lyra, Edmonds, Kim, Lingard, Karla, Sarker, Sarah, Attig, Jan, Joshi, Kroopa, Uddin, Imran, Becker, Pablo D., Sunderland, Mariana Werner, Akarca, Ayse, Puccio, Ignazio, Yang, William W., Lund, Tom, Dhillon, Kim, Vasquez, Marcos Duran, Ghorani, Ehsan, Xu, Hang, Spencer, Charlotte, López, José I., Green, Anna, Mahadeva, Ula, Borg, Elaine, Mitchison, Miriam, Moore, David A., Proctor, Ian, Falzon, Mary, Pickering, Lisa, Furness, Andrew J.S., Reading, James L., Salgado, Roberto, Marafioti, Teresa, Jamal-Hanjani, Mariam, Kassiotis, George, Chain, Benny, Larkin, James, Swanton, Charles, Quezada, Sergio A., and Turajlic, Samra

Published
2021
Full Text
View/download PDF

27. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Author

Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, and Baas, Paul

Published
2021
Full Text
View/download PDF

28. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Author

Lindsay, Colin R., Shaw, Emily C., Moore, David A., Rassl, Doris, Jamal-Hanjani, Mariam, Steele, Nicola, Naheed, Salma, Dick, Craig, Taylor, Fiona, Adderley, Helen, Black, Fiona, Summers, Yvonne, Evans, Matt, Rice, Alexandra, Fabre, Aurelie, Wallace, William A., Nicholson, Siobhan, Haragan, Alex, Taniere, Phillipe, Nicholson, Andrew G., Laing, Gavin, Cave, Judith, Forster, Martin D., Blackhall, Fiona, Gosney, John, Popat, Sanjay, and Kerr, Keith M.

Published
2021
Full Text
View/download PDF

30. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Author

Walls, Gerard M., Oughton, Jamie B., Chalmers, Anthony J., Brown, Sarah, Collinson, Fiona, Forster, Martin D., Franks, Kevin N., Gilbert, Alexandra, Hanna, Gerard G., Hannaway, Nicola, Harrow, Stephen, Haswell, Tom, Hiley, Crispin T., Hinsley, Samantha, Krebs, Matthew, Murden, Geraldine, Phillip, Rachel, Ryan, Anderson J., Salem, Ahmed, Sebag-Montefoire, David, Shaw, Paul, Twelves, Chris J., Walker, Katrina, Young, Robin J., Faivre-Finn, Corinne, and Greystoke, Alastair

Published
2020
Full Text
View/download PDF

31. Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

Author

Abbosh, Chris, Shiu, Kai-Keen, Bridgewater, John, Hochhauser, Daniel, Forster, Martin, Lee, Siow-Ming, Ahmad, Tanya, Papadatos-Pastos, Dionysis, Janes, Sam, Van Loo, Peter, Enfield, Katey, McGranahan, Nicholas, Huebner, Ariana, Quezada, Sergio, Beck, Stephan, Parker, Peter, Walczak, Henning, Enver, Tariq, Hynds, Rob, Falzon, Mary, Proctor, Ian, Sinclair, Ron, Lok, Chi-wah, Rhodes, Zoe, Moore, David, Marafioti, Teresa, Borg, Elaine, Mitchison, Miriam, Khiroya, Reena, Trevisan, Giorgia, Ellery, Peter, Linch, Mark, Brandner, Sebastian, Hiley, Crispin, Veeriah, Selvaraju, Razaq, Maryam, Shaw, Heather, Attard, Gert, Akther, Mita Afroza, Naceur-Lombardelli, Cristina, Manzano, Lizi, Al-Bakir, Maise, Summan, Simranpreet, Kanu, Nnenna, Ward, Sophie, Asghar, Uzma, Lim, Emilia, Gishen, Faye, Tookman, Adrian, Stone, Paddy, Stirling, Caroline, Furness, Andrew, Edmonds, Kim, Hunter, Nikki, Sarker, Sarah, Vaughan, Sarah, Mangwende, Mary, Pearce, Karla, Spain, Lavinia, Shepherd, Scott, Yan, Haixi, Shum, Ben, Carlyle, Eleanor, Hazell, Steve, Fendler, Annika, Byrne, Fiona, Yousaf, Nadia, Popat, Sanjay, Curtis, Olivia, Stamp, Gordon, Toncheva, Antonia, Nye, Emma, Murra, Aida, Korteweg, Justine, Sheikh, Nahid, Josephs, Debra, Chandra, Ashish, Spicer, James, Mahadeva, Ula, Green, Anna, Stewart, Ruby, Iredale, Lara-Rose, Mackay, Tina, Deakin, Ben, Enting, Debra, Rudman, Sarah, Ghosh, Sharmistha, Karapagniotou, Lena, Pintus, Elias, Tutt, Andrew, Howlett, Sarah, Michalarea, Vasiliki, Brenton, James, Caldas, Carlos, Fitzgerald, Rebecca, Jimenez-Linan, Merche, Provenzano, Elena, Cluroe, Alison, Stewart, Grant, Watts, Colin, Gilbertson, Richard, McDermott, Ultan, Tavare, Simon, Beddowes, Emma, Roxburgh, Patricia, Biankin, Andrew, Chalmers, Anthony, Fraser, Sioban, Oien, Karin, Kidd, Andrew, Blyth, Kevin, Krebs, Matt, Blackhall, Fiona, Summers, Yvonne, Dive, Caroline, Marais, Richard, Gomes, Fabio, Carter, Mat, Dransfield, Jo, Le Quesne, John, Fennell, Dean, Shaw, Jacqui, Naidu, Babu, Baijal, Shobhit, Tanchel, Bruce, Langman, Gerald, Robinson, Andrew, Collard, Martin, Cockcroft, Peter, Ferris, Charlotte, Bancroft, Hollie, Kerr, Amy, Middleton, Gary, Webb, Joanne, Kadiri, Salma, Colloby, Peter, Olisemeke, Bernard, Wilson, Rodelaine, Tomlinson, Ian, Jogai, Sanjay, Ottensmeier, Christian, Harrison, David, Loda, Massimo, Flanagan, Adrienne, McKenzie, Mairead, Hackshaw, Allan, Ledermann, Jonathan, Sharp, Abby, Farrelly, Laura, Bridger, Hayley, Litchfield, Kevin, Stanislaw, Stacey, Gallegos, Lisa L., Rowan, Andrew, Schnidrig, Desiree, Rosenbaum, Heidi, Harle, Alexandre, Au, Lewis, Hill, Samantha M., Tippu, Zayd, Thomas, Jennifer, Thompson, Lisa, Xu, Hang, Horswell, Stuart, Barhoumi, Aoune, Jones, Carol, Leith, Katherine F., Burgess, Daniel L., Watkins, Thomas B.K., Birkbak, Nicolai J., Lamy, Philippe, Nordentoft, Iver, Dyrskjøt, Lars, Pickering, Lisa, Hazell, Stephen, Jamal-Hanjani, Mariam, Larkin, James, Swanton, Charles, Alexander, Nelson R., and Turajlic, Samra

Published
2020
Full Text
View/download PDF

33. 102 Hepatitis B and HIV screening prior to first systemic anticancer therapy (SACT) in an inner-city London thoracic cancer population.

Author

Buckley, Thomas, primary, Lucas, Tylan, additional, Odita, Malcolm, additional, Masento, Sebastian, additional, Benafif, Sarah, additional, Forster, Martin, additional, Hiley, Crispin, additional, Jamal-Hanjani, Mariam, additional, Keshwani, Karim, additional, Lee, Siow Ming, additional, Papadatos-Pastos, Dionysis, additional, Swanton, Charlie, additional, Wilson, James, additional, Ahmad, Tanya, additional, and Hughes, Daniel Johnathan, additional

Published
2024
Full Text
View/download PDF

34. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Author

Janku, Filip, primary, Choong, Grace M., additional, Opyrchal, Mateusz, additional, Dowlati, Afshin, additional, Hierro, Cinta, additional, Rodon, Jordi, additional, Wicki, Andreas, additional, Forster, Martin D., additional, Blagden, Sarah P., additional, Yin, Jun, additional, Reid, Joel M., additional, Muller, Helene, additional, Cmiljanovic, Natasa, additional, Cmiljanovic, Vladimir, additional, and Adjei, Alex A., additional

Published
2024
Full Text
View/download PDF

35. Multi-institutional, International Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma

Author

Saraswathula, Anirudh, additional, Ullah, Mohammed N., additional, Liu, Jacklyn, additional, Takahashi, Yoko, additional, Mahajan, Arushi, additional, Battocchio, Simonetta, additional, Bossi, Paolo, additional, Castelnuovo, Paolo, additional, Facchetti, Fabio, additional, Facco, Carla, additional, Ferrari, Marco, additional, Forster, Martin D., additional, Franchi, Alessandro, additional, Jay, Amrita, additional, Lombardi, Davide, additional, Lund, Valerie J., additional, Mattavelli, Davide, additional, Nicolai, Piero, additional, Rampinelli, Vittorio, additional, Sessa, Fausto, additional, Su, Shirley, additional, Turri-Zanoni, Mario, additional, Vermi, William, additional, McKean, Erin, additional, Lechner, Matt, additional, Hanna, Ehab, additional, and London, Nyall R, additional

Published
2024
Full Text
View/download PDF

36. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

Author

Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, and Lopez, Juanita

Published
2020
Full Text
View/download PDF

37. The National Lung Matrix Trial of personalized therapy in lung cancer

Author

Middleton, Gary, Fletcher, Peter, Popat, Sanjay, Savage, Joshua, Summers, Yvonne, Greystoke, Alastair, Gilligan, David, Cave, Judith, O’Rourke, Noelle, Brewster, Alison, Toy, Elizabeth, Spicer, James, Jain, Pooja, Dangoor, Adam, Mackean, Melanie, Forster, Martin, Farley, Amanda, Wherton, Dee, Mehmi, Manita, Sharpe, Rowena, Mills, Tara C., Cerone, Maria Antonietta, Yap, Timothy A., Watkins, Thomas B. K., Lim, Emilia, Swanton, Charles, and Billingham, Lucinda

Published
2020
Full Text
View/download PDF

38. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

Author

Lechner, Matt, Schartinger, Volker H., Steele, Christopher D., Nei, Wen Long, Ooft, Marc Lucas, Schreiber, Liesa-Marie, Pipinikas, Christodoulos P., Chung, Grace Tin-Yun, Chan, Yuk Yu, Wu, Feng, To, Ka-Fai, Tsang, Chi Man, Pearce, Wayne, Morelli, Daniele, Philpott, Martin, Masterson, Liam, Nibhani, Reshma, Wells, Graham, Bell, Christopher G., Koller, Julia, Delecluse, Susanne, Yip, Yim Ling, Liu, Jacklyn, Forde, Cillian T., Forster, Martin D., Jay, Amrita, Dudás, József, Krapp, Annika, Wan, Simon, Uprimny, Christian, Sprung, Susanne, Haybaeck, Johannes, Fenton, Tim R., Chester, Kerry, Thirlwell, Christina, Royle, Gary, Marafioti, Teresa, Gupta, Rajeev, Indrasari, Sagung Rai, Herdini, Camelia, Slim, Mohd Afiq Mohd, Indrawati, I., Sutton, Liam, Fles, Renske, Tan, Bing, Yeong, Joe, Jain, Amit, Han, Shuting, Wang, Haitao, Loke, Kelvin S. H., He, Wan, Xu, Ruilian, Jin, Hongtao, Cheng, Zhiqiang, Howard, David, Hwang, Peter H., Le, Quynh-Thu, Tay, Joshua K., West, Robert B., Tsao, Sai Wah, Meyer, Tim, Riechelmann, Herbert, Oppermann, Udo, Delecluse, Henri-Jacques, Willems, Stefan M., Chua, Melvin L. K., Busson, Pierre, Lo, Kwok Wai, Wollmann, Guido, Pillay, Nischalan, Vanhaesebroeck, Bart, and Lund, Valerie J.

Published
2021
Full Text
View/download PDF

41. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Author

de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, and Lassen, Ulrik

Published
2019
Full Text
View/download PDF

42. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

Author

Pinato, David James, primary, Jones, Robert Hugh, additional, Forster, Martin D., additional, Joshua, Anthony M., additional, Korolewicz, James, additional, Benafif, Sarah, additional, Aboud, Karam, additional, Liu, Jia (Jenny), additional, Cosman, Rasha, additional, Paull, Jeremy, additional, Fairley, Jacinth, additional, Edmondson, Stephanie Ruth, additional, and Spicer, James F., additional

Published
2024
Full Text
View/download PDF

44. The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial.

Author

Welch, Charlie, Forster, Martin, Ronaldson, Sarah, Keding, Ada, Corbacho-Martín, Belen, and Tharmanathan, Puvan

Subjects
*EXPERIMENTAL design, *HAND osteoarthritis, *COST effectiveness, *MISSING data (Statistics), *KNEE pain
Abstract

Background: There is increasing interest in the capacity of adaptive designs to improve the efficiency of clinical trials. However, relatively little work has investigated how economic considerations – including the costs of the trial – might inform the design and conduct of adaptive clinical trials. Methods: We apply a recently published Bayesian model of a value-based sequential clinical trial to data from the 'Hydroxychloroquine Effectiveness in Reducing symptoms of hand Osteoarthritis' (HERO) trial. Using parameters estimated from the trial data, including the cost of running the trial, and using multiple imputation to estimate the accumulating cost-effectiveness signal in the presence of missing data, we assess when the trial would have stopped had the value-based model been used. We used re-sampling methods to compare the design's operating characteristics with those of a conventional fixed length design. Results: In contrast to the findings of the only other published retrospective application of this model, the equivocal nature of the cost-effectiveness signal from the HERO trial means that the design would have stopped the trial close to, or at, its maximum planned sample size, with limited additional value delivered via savings in research expenditure. Conclusion: Evidence from the two retrospective applications of this design suggests that, when the cost-effectiveness signal in a clinical trial is unambiguous, the Bayesian value-adaptive design can stop the trial before it reaches its maximum sample size, potentially saving research costs when compared with the alternative fixed sample size design. However, when the cost-effectiveness signal is equivocal, the design is expected to run to, or close to, the maximum sample size and deliver limited savings in research costs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Author

Acosta-Rivera, Mirelis, Adkins, Douglas R., Aghmesheh, Morteza, Ahn, Myung-Ju, Airoldi, Mario, Aleknavicius, Eduardas, Al-Farhat, Yousuf, Algazi, Alain P., Almokadem, Salah, Alyasova, Anna, Bauman, Jessica R., Benasso, Marco, Berrocal, Alfonso, Bray, Victoria, Burtness, Barbara Ann, Caponigro, Francesco, Castro, Ana, Cescon, Terrence P., Chan, Kelvin, Chaudhry, Arvind, Chauffert, Bruno, Cohen, Ezra, Csoszi, Tibor, De Boer, J.P., Delord, Jean-Pierre, Dietz, Andreas, Dinis, Jose, Dupuis, Charlotte, Digue, Laurence, Erfan, Jozsef, Escobar Alvarez, Yolanda, Evans, Mererid, Fidler, Mary Jo, Forster, Martin David, Friesland, Signe, Ganti, Apar K., Geoffrois, Lionnel, Grant, Cliona, Gruenwald, Viktor, Harrington, Kevin, Hoffmann, Thomas, Horvai, Geza, Inciura, Arturas, Jang, Raymond, Jankowska, Petra, Jimeno, Antonio, Joseph, Mano, Juarez Ramiro, Alejandro, Karaszewska, Boguslawa, Kawecki, Andrzej, Keilholz, Ulrich, Keller, Ulrich, Kim, Sung-Bae, Kocsis, Judit, Kotecki, Nuria, Kozloff, Mark F., Lambea, Julio, Landherr, Laszlo, Lantsukhay, Yuri, Lazarev, Sergey Alexandrovich, Lee, Lip Way, Le Tourneau, Christophe, Licitra, Lisa, Lifirenko, Igor Dmitrievich, Mach, Nicolas, Martincic, Danko, Matorin, Oleg Vladmirovhich, McGrath, Margaret, Machiels, Jean-Pascal, Mehra, Ranee, Misiukiewicz, Krzysztof, Morris, John C., Mufazalov, Fagim Fanisovich, Niu, Jiaxin, Pamoorthy Srinivasan, Devraj, Perez Segura, Pedro, Rauch, Daniel, Ribeiro, Maria Leonor, Rodriguez, Cristina, Rolland, Frederic, Russo, Antonio, Ruzsa, Agnes, Sanches, Frederico, Shin, Sang-Won, Shtiveland, Mikhail, Soulieres, Denis, Soria, Ainara, Specenier, Pol, Szekanecz, Eva, Szota, Judit, van Herpen, Carla M.L., Velez-Cortes, Hector A., Walsh, William V., Wilop, Stefan, Winterhalder, Ralph, Wojtukiewicz, Marek, Wong, Deborah, Zandberg, Dan, Cohen, Ezra E W, Soulières, Denis, Dinis, José, Burtness, Barbara, Zhang, Pingye, Cheng, Jonathan, Swaby, Ramona F, and Harrington, Kevin J

Published
2019
Full Text
View/download PDF

46. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Author

Moleron, Rafael, McArdle, Orla, Dyker, Karen, Al Booz, Hoda, O'Toole, Lorcan, Cook, Audrey, Husband, David, Loo, Vivienne, Soe, Win, Aynsley, Eleanor, Sridhar, Thiagarajan, Jankowska, Petra, Joseph, Mano, Geropantas, Konstantinos, Vaidya, Deepali, Griffin, Matthew, Hartley, Andrew, Vijayan, Rengarajan, Hwang, David, Harrington, Kevin, Pettit, Laura, Whitaker, Stephen, De Winton, Emma, Rolles, Martin, Brennan, Sinéad, Sen, Mehmet, Mendes, Ruheena, Forster, Martin, Chan, Andrew, Evans, Mererid, Buter, Jan, Srinivasan, Devraj, Foran, Bernie, Nankivell, Paul, Bryant, Jennifer, Sharma, Neil, Spruce, Rachel, Brooks, Jill, Batis, Nikos, Roques, Tom, Bidmead, Margaret, Yang, Huiqi, Nutting, Christopher, Tyler, Justine, Henderson, Julia, Baines, Helen, Gasnier, Anne, Miles, Elizabeth, Clark, Catharine, Mehanna, Hisham, Robinson, Max, Kong, Anthony, Foran, Bernadette, Fulton-Lieuw, Tessa, Dalby, Matthew, Mistry, Pankaj, Brennan, Sinead, Nixon, Ioanna, Grumett, Joanne, Leemans, C René, McConkey, Christopher, Gray, Alastair, and Dunn, Janet

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results